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The National Occupational Research
Agenda (NORA) was established by the
National Institute for Occupational Safety
and Health (NIOSH) in 1996 with input
from more than 500 organizations and indi-
viduals. Since its inception, NORA has
become a prototype for advancing research
in the area of worker safety and health. It is
the largest single source of support for 21
occupational research priority areas. The
goal of the cancer research methods priority
area is to identify, evaluate, and recommend
new technologies designed to better control
and help investigators understand occupa-
tional carcinogenesis. This ongoing effort
has coincided with a revolution in biology.
The human genome map has just been
completed, and it has arrived with a wealth
of new biologic methods that drove or were
driven by the goal to complete the mapping.
Despite this increase in new technologies
and methods, they have yet to be applied
fully to occupational cancer research (Ward
et al. 2003). To address this gap, a work-
shop, “Applying New Biotechnology to the
Study of Occupational Cancer,” was spon-
sored by NIOSH in conjunction with the
National Cancer Institute (NCI), the
National Institute of Environmental Health
Sciences (NIEHS), and the American
Chemistry Council (ACC). The workshop
brought together researchers studying
worker populations and those developing
and validating new biotechnologies. The
workshop focused on four topics: a) the
challenge of applying new biotechnologies
to the study of occupational cancer,
b) markers of early biologic effect, c) inher-
ited modifiers of risk, and d) applying
genetic biomarkers to human studies.
Challenge of Applying New
Biotechnologies to the Study
of Occupational Cancer
Epidemiology in the 21st century. A pri-
mary challenge in applying new biotech-
nologies to occupational cancer research is
including them within the framework of
classic studies of occupational exposure and
effect. Historically, occupational studies
have helped identify many of the recognized
environmental carcinogens, resulting in
reduced exposure for both workers and the
general population. Studies of carcinogens
in occupational populations were facilitated
by the availability of records of employees
and the high and prolonged exposures they
experienced, which often resulted in high
relative risks for speciﬁc cancers. Challenges
to occupational cancer epidemiology in the
21st century relate to the changing nature of
the workplace and the complexity of the
exposures. As a result of regulations and
industry efforts, exposure levels are much
lower than in the past. Many exposures are
mixtures, and many industries involve expo-
sures to an ever-changing and diverse array
of substances. These changes create the need
for more sensitive measures to detect cancer
risks. To move the ﬁeld of occupational can-
cer research forward, it will be necessary to
a) conduct more studies of occupational
cancer among women and minorities, as
these populations have been ignored in the
past; b) perform quantitative exposure
assessments, as qualitative exposure assess-
ments that rely on general classification of
occupation are not good enough; c) examine
interactions between occupational exposures
and nonoccupational exposures, as cancer is
a multi-faceted disease; d) focus on biologic
tissues and mechanisms of action and incor-
porate gene–environmental assessments into
traditional exposure disease paradigms used
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Toxicogenomics Workshop Summaryin epidemiology; and e) integrate epidemiol-
ogy, toxicology, genetics, and quantitative
exposure assessment.
The promise of new biotechnologies.
The progression from exposure to disease is
typically expressed as a continuum of envi-
ronmental exposure → internal dose →
biologically effective dose → early biologic
effect → altered structure and function →
and finally clinical disease. Each step is
affected by a person’s susceptibility, and
the continuum provides multiple opportu-
nities for application of biomarkers for
early prediction of disease. Although
applicable to biomarkers of exposure, the
new technologies apply primarily to bio-
markers of early effect and susceptibility.
Biomarkers that measure early effect and
susceptibility can be used in selecting study
cohorts, assessing participant compliance,
or determining intervention effectiveness.
The effective use of biomarkers include
optimizing reliability, precision, accuracy,
and validity. Not all biomarkers are suit-
able for all purposes and are likely to be
imperfect in any single setting. The greatest
potential for new biomarkers of early effect
in occupational hazard assessment lies in
toxicogenomics, which can be deﬁned as a
ﬁeld of study that examines how the entire
genome responds to toxicants or other
environmental hazards. Toxicogenomics
applies genomics, gene and protein expres-
sion profiling, metabolite profiling or
metabonomics, and bioinformatics to
understand gene–environment interactions
and disease. The many genomic-related
technologies, often referred to simply as
“omics,” allow exploration of multiple
interactions between genetic and environ-
mental factors. This exploration will
improve the understanding of mechanisms
of action, clarify the use and limitations of
surrogate models, enhance predictive toxi-
cology and screening, and better character-
ize susceptible populations.
Technical and policy issues. The fields
of toxicology and epidemiology are crucial
for the assessment and management of the
impact of chemicals on the safety, health,
and welfare of workers. To realize this, a
uniﬁed research agenda is needed for devel-
oping new technologies that will be used
within a framework of toxicologic and epi-
demiologic principles. To accomplish this,
the involvement of stakeholder communi-
ties is needed to address social, legal, and
ethical issues (Henry et al. 2002). Technical
and policy issues that need to be addressed
include a) opportunities for shared learning
in the public domain, b) accessibility to
publicly held gene expression databases,
c) understanding of the predictive capabili-
ties of the technologies before widespread
application, d)a vailability of prevalence
data, e) privacy and confidentiality con-
cerns, f) security and discrimination issues,
g) counseling for coping with genetic infor-
mation, h) use and premature use of
“omics” data, and i) deﬁning the regulatory
positions on “omics” data. Researchers need
to focus on methods to assess gene expres-
sion in large populations, address statistical
and bioinformatics issues, and use a multi-
disciplinary approach. These actions will
lead to better integration of toxicology and
epidemiology.
Markers of Early Biologic
Effects
Rationale for assessing intermediate bio-
markers. Epidemiologists have begun
employing early markers of effect because
of the challenges in using cancer as an out-
come measure in occupational epidemio-
logic studies. There is minimal ambiguity
when clinical disease is an end point, but
there are limitations when studying cancer.
The foremost problem is latency—the 10,
20, or even 30 years between exposure and
disease. This latency moved researchers to
develop the field of molecular epidemiol-
ogy 20 years ago. The growth in molecular
epidemiology was due to the promise that a
new generation of biologic markers, with
particular application to occupational can-
cer, would allow one to identify excess risk
early in the natural history of a disease and
provide an opportunity for preventive
action. Other potential benefits of early
markers of disease include the ability to
enhance exposure assessment, especially
low-dose exposures and low-risk popula-
tions, identify risks from single agents
within complex exposures, estimate the
total exposure from multiple sources, and
provide data today that predict tomorrow’s
effects. While these beneﬁts are important,
in reality, many individual biomarkers may
never provide a definitive answer linking
exposure to disease. These markers may
have the greatest impact in providing addi-
tional information to the weight of evi-
dence that suggests a particular exposure is
a potential risk. 
A good example is the p53 mutations in
angiosarcomas associated with vinyl chlo-
ride-exposed factory workers. These lesions
are specific to the tumors in persons with
vinyl chloride exposure and are not evident
in liver angiosarcomas of persons without
vinyl chloride exposure. Therefore, these
p53 lesions serve as a molecular ﬁngerprint
of exposure. Other examples are not so
clear. Attempts to use the glycophorin A
locus somatic cell mutation as an end point
of a specific locus mutation arising from
exposures to benzo[a]pyrene or styrene was
confounded by the high background of this
mutation in cigarette smokers. Therefore,
two things are needed to reach exposure-
specific inferences. The first is a prevalent
and speciﬁc genetic lesion that can be iden-
tified in an occupationally exposed group,
and the second is a low background of the
lesion in the general population.
Validation and linking intermediate
biomarkers to cancer. The difﬁcult steps to
validation of early biomarkers begin with
animal studies and includes studies that
ensure biomarker reliability before moving
to human subjects with case–control and
cohort approaches. Validating biomarkers
as predictors requires large study popula-
tions in order to investigate events that are
generally uncommon. The premier exam-
ples are recent cohort studies on DNA
adducts and chromosomal aberrations
(Bonassi et al. 2000). Biomarkers validated
through longitudinal human studies can be
used efﬁciently to estimate the risk of can-
cer in populations in which epidemiologic
studies cannot be performed. 
The establishment of a correlation
between chromosomal aberrations in
peripheral lymphocytes and cancer has
stimulated the development of new tech-
niques to detect aberrations in a variety of
exposed populations. This is because scor-
ing of unbanded chromosomes in meta-
phase preparations to detect aberrations is
labor intensive and prone to technical arti-
facts. Therefore, the micronucleus assay has
become popular as it is faster, inexpensive,
and can be performed on virtually any cell
type. Unfortunately, an association has not
been established between micronuclei in
peripheral blood lymphocytes and a risk for
human cancers, as is the case with chromo-
somal aberrations. Therefore, validation
studies with micronuclei and other end
points are needed. Other alternatives
include fluorescent in situ hybridization
(FISH), which is relatively fast to perform,
with costs ranging from inexpensive to
moderately expensive. A more comprehen-
sive type of FISH is multicolor karyotyp-
ing, spectral karyotyping (SKY) or
M-FISH, which can identify aberrations in
all chromosomes. These techniques are
equipment and labor intensive and remain
too costly for large-scale use. To be useful
for occupational cancer research in the
future, cytogenetic techniques will need to
incorporate automation, rapid-image
analysis, and ﬂow cytometry so that a large
number of samples can be processed for
modest cost.
Monitoring changes in gene expression.
Carcinogens presumably disrupt gene
expression, resulting in a wide interindivid-
ual variation in response. Demonstrating a
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expression profiles could pave the way for
the use of carcinogen-induced changes in
transcription as biomarkers to assess worker
risk. Ideally, early biologic effect markers
can be used to evaluate risk in groups of
workers exposed to chemicals and other
insults. Advantages of using markers of
early biologic effects in cancer etiology
studies are that fewer persons may be
needed than in a cohort study that evalu-
ates cancer as an outcome. Studies can be
performed quickly, as they are generally
cross-sectional or short-term longitudinal
investigations. Also, because recent expo-
sure often has the greatest impact on early
biologic effect biomarkers, highly accurate
exposure assessment can be achieved. 
In identifying environmental factors in
the induction of human disease, one is con-
fronted with thousands of chemicals, dose-
and time-related effects, multiple genetic
substrates, and uncertainty about disease
models. The simple model of a normal cell
experiencing several genetic events to
become cancerous is outdated. Innumerable
genetic and other events must occur. To
assess the effects of low-level exposure, it
will be necessary to examine multiple
gene–environment interactions to demon-
strate that the cancer risk is related to a
speciﬁc exposure.
The complexity of gene–environment
interactions is exemplified by simple gene
expression studies conducted in isolated
cells. The response to benzo[a]pyrene of
approximately 7,000 genes in primary
epithelial cells from multiple human
donors revealed altered (both increases and
decreases) expression patterns (> 100%
change) in more than 500 RNA species.
Dose- and time-dependent changes in
expression were noted in cytochrome P450
metabolism enzymes, other carcinogen
metabolism genes, DNA repair genes, and
cell-cycle regulation genes such as p52 and
p21. Analysis of the many changes in
expression is enhanced by cluster analysis,
which is an algorithm designed to identify
patterns of expression. It groups RNA tran-
scripts that respond to test treatments in
similar fashion and organizes a map ideally
suited to large data set analysis. Such analy-
ses are necessary for rapid and effective
interrogation of thousands of genes. As
outcome data expand exponentially, new
data analysis, storage, and mining strategies
will be needed. To understand mechanisms
of toxicity and predict the toxicity of new
chemicals, a reference knowledge base will
be needed that anchors gene expression
patterns, proteomic data, and metabolite
profiles to conventional toxicology and
pathology determinations. Linkages need
to include information about dose, route,
time, and target tissue as well as informa-
tion about early, middle, and late toxicity-
related changes. Databases need to be easily
accessible and provide chemical-signature
analyses so that unknown toxicants can be
queried within the database to determine
their potential toxicity. 
Inherited Modiﬁers of Risk
Identification of relevant genes. The
influence of genetic factors on susceptibil-
ity to cancer is widely recognized. Some
well-known genetic risk factors, such as the
BRCA1 gene, result in a high absolute risk
of cancer in persons with the gene.
Susceptibility to environmental carcino-
gens is likely to be influenced by a multi-
tude of genes, none of which alone has a
very large effect. Moreover, the cumulative
effect on susceptibility to a class of environ-
mental toxicants may result from complex
interactions of multiple genes. Historically,
studies have focused on what the body does
in terms of absorption, distribution,
metabolism, and excretion of environmen-
tal agents (pharmacokinetics). More
recently, emphasis has been on what the
agent does to the body (pharmacodynam-
ics). Environmental agents can act either as
agonists or antagonists or as activators or
inhibitors, thereby perturbing normal func-
tion. To be applicable to risk assessment,
polymorphisms of susceptibility will have
to be included in models that define a
chemical’s adverse effects.
Identification of SNPS. All genes are
highly polymorphic and, perhaps, every
gene is capable of being an environmental
susceptibility gene. DNA sequence variants
include single-nucleotide polymorphisms
(SNPs), insertions and deletions, or inver-
sions and duplications of multiple bases or
repetitive DNA. As many as 10 million
SNPs are estimated to exist per person,
many of which are population specific.
Although most SNPs have no phenotypic
effect, approximately 50,000 to 250,000
SNPs bear a phenotypic change. In the past,
geneticists searched for signiﬁcant penetrant
mutations that explain rare diseases. Many
of these monogenetic disorders occur against
the background of SNPs that function as
modiﬁers of outcome. Similar strategies are
used to dissect the genetic contribution to
complex diseases, especially those with
important environmental exposures.
Technical advances make possible the study
of large collections of SNPs from either
known genes and pathways or those distrib-
uted randomly across chromosome(s). In
this regard, future studies will examine genes
up and downstream to the candidate gene.
The scope of studies has evolved from
single-gene design with a phenotype measure-
ment to the promise of surveying the whole
genome with “dense-SNP scans.” Public
SNP databases such as NCBI dbSNP data-
base (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=snp), which contains about
3.5 million randomly generated SNPs, will
be essential to this research. The NCI has
developed the Cancer Genome Anatomy
Project (http://cgap.nci.nih.gov). Two fea-
tures of this program are to identify SNPs
in silico and validate SNPs by sequence
analysis (http://snp500cancer.nci.nih.gov).
In the future, publicly available integrated
databases need to be built on environmental
exposures, SNPs, important genes, and mea-
sured disease outcomes. The field will
advance only with substantial collaboration
and meta-analyses. Genetic databases must
be crossed with those addressing exposure
and disease.
Applying Genetic Biomarkers
to Human Studies
A primary goal for assessing gene expression
responses is the identification of candidate
exposure biomarkers. Undoubtedly, pertur-
bations in RNA expression and protein pat-
terns will be noted in exposed persons.
However, uncertainty will exist as to their
use in predicting disease. It is not a given
that changes in gene expression will make a
difference in a risk-related outcome.
Physiologically based pharmacokinetic
models have demonstrated that 10-fold dif-
ferences in enzyme levels may make little
difference in bioactivation of a chemical, as
the chemical is completely metabolized at
low doses in the absence of enzyme induc-
tion. The application of data to risk assess-
ment will be aided by the development of
models of gene expression of oncogenes and
tumor suppressor genes and modeling of
polymorphisms of susceptibility. One
potential approach will be to group chemi-
cals with similar global gene expression pro-
files (GGEP) and use available cancer
bioassays on these chemicals to derive rela-
tive potency parameters in dose–response
models. More broadly, GGEP can be used
to link chemicals that induce similar
enzymes or adverse effects to derive relative
potency estimates. Mutations found in
oncogenes or tumor suppressor genes may
be used to develop dose–response models
for humans. The application of biomarkers
to risk assessment will require a clear under-
standing of how environmental exposure
indices such as air concentrations and
markers of early biologic effects are linked
through biomarkers of exposure. 
Exposure assessment. Once intermedi-
ate markers and underlying pathways are
known, the dose–response relationship and
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requires detailed exposure assessment for
which cross-sectional biomarker studies are
useful. When environmental measures are
not available, exposure assessments need to
rely on the body burden of a compound.
To understand the exposure–response rela-
tionship, it is necessary to understand the
relationship between environmental con-
centrations of a compound and a measure
of body burden or a biomarker that can be
a reactive intermediate, a stable metabolite,
or a macromolecular adduct. These are ran-
dom variables capable of varying both
within and between subjects in a popula-
tion. The key to understanding biomarkers
of exposure is a categorization of biomark-
ers by their half-lives. Short-term biomark-
ers have residence times or half-lives of less
than 30 hr; longer-term biomakers have
half-lives greater than a thousand hours;
and intermediate-term biomarkers are in
between. These distinctions are for conve-
nience in relating exposure concentrations
to biomarker levels. Since intermediate and
long-term biomarkers provide information
about exposures over weeks to years, a
small number of biomarker measurements
can be sufficient to assess exposure. In
some cases, new technologies will be bene-
ﬁcial in assessing risk of occupational expo-
sure to complex mixtures or a variety of
agents simultaneously (mixed exposures).
High throughput technologies may help
identify those agents within a complex
mixture or mixed exposure that are respon-
sible for observed cancer risks, the level of
risk associated with the various agents, the
agent driving the risk, and the mechanisms
of action. These could be investigated by
comparing patterns of genetic changes in
tissue exposed to mixtures with known pat-
terns for suspect agents. To achieve this
capability, it will be necessary to go beyond
hypothesis testing and conduct discovery-
based research. 
Ethics and the use of new technologies.
As genotyping and epidemiologic studies
become an integral part of occupational
disease prevention and control, fear of pri-
vacy violations and discrimination in
employment will increase. Issues that arise
with the ability to identify markers of
disease susceptibility include employment
eligibility, insurability, employer abuse,
permissible exposure limits, privacy legisla-
tion, and structure of human subject
review boards. According to a U.S.
Congress Ofﬁce of Technology Assessment
report (1992), 55% of commercial insur-
ance carriers did not consider a genetic dis-
ease trait a preexisting disease. In contrast,
75% of health maintenance organizations
did. Another study reported that gene test-
ing results were interpreted correctly only
68% of the time (Giardiello et al.1997).
These perceived disparities in perspective
and potential for erroneous results heighten
public concerns about genetic research. A
gene for beryllium disease is an example of
a genetic marker that raises legal and ethi-
cal issues. Apparently, 30% of the general
population carries a gene placing them at
high risk for disease, even if exposed to low
concentrations of beryllium. Although pre-
employment screening is possible, testing
of this gene has been confined to research
studies. However, no federal law prohibits
employers from acquiring genetic informa-
tion if a prospective employee signs a medi-
cal release. Laws need to be written to
protect the pubic while at the same time
not restricting research, which would have
a negative impact on public health.
Researchers should become more actively
involved with the ethical and policy impli-
cations of their work. To achieve this, they
should a) ensure correct application of
research in the clinical or occupational set-
ting; b) protect conﬁdentiality and privacy;
c) provide appropriate feedback for sub-
jects; d) improve the language of informed
consent forms; e) define guidelines for
sample archiving (when to preserve or
destroy links); f ) guard against undue
influence from commercial interests;
g) reduce the stigma associated with assess-
ing gene polymorphisms; h) consider the
environmental and occupational regulatory
implications of research findings; and
i) contribute to the development of federal
laws addressing access, disclosure, or stor-
age of genetic information by employers. 
Summary
The ability of new biotechnologies to
group chemicals with similar global gene
expression profiles has the potential to
provide an early warning system for sus-
pected carcinogens before they are intro-
duced into commerce. The challenge will
be to identify the degree of similarity
required to predict carcinogenicity and to
distinguish pathogenic patterns from
homeostatic ones. Gene expression pat-
terns will likely be used in epidemiologic
studies as surrogate end points for cancer.
Attention to basic epidemiologic principles
of design and analysis are still important to
guard against biases and irreproducible
results. To enhance risk assessments,
expression patterns need to demonstrate
comparability across species for extrapola-
tion purposes, and to be robust at different
doses for dose–response predictions.
Before these technologies are used in
humans, the ethical, legal, and social issues
should be addressed along with the scien-
tific issues. The ultimate challenge to the
occupational safety and health community
is how to exploit new technologies appro-
priately without disregarding the potential
benefits of traditional “low-tech” research
approaches. Meeting this challenge will
require the integration of historically
tested technologies with newer ones. 
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